Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report

Abstract : In patients with age-related macular degeneration (AMD), the intravitreal injection of antivascular endothelial growth factor (anti-VEGF) agents reduces disease progression and choroidal neovascularization. We report on a first case of ischaemic colitis associated with intravitreal injection of the anti-VEGF agent aflibercept in an 80-year-old female patient. Conservative treatment resulted in a favourable clinical outcome. The anti-VEGF agent was discontinued, and the symptoms did not recur. Although the intravitreal injection of anti-VEGF agents has not previously been linked to the occurrence of ischaemic colitis, consideration of aflibercept's pharmacological properties and the chronological relationship between the administration of this anti-VEGF agent and the occurrence of this systemic adverse event are strongly suggestive of a causal relationship in the present case. Although systemic complications have been rarely associated with intravitreal injections of anti-VEGF agents, physicians should be aware that novel adverse events can still occur in AMD patients treated with anti-VEGF agents.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : jeudi 10 février 2022 - 15:59:03
Dernière modification le : jeudi 25 août 2022 - 11:22:40

Lien texte intégral




Benjamin Batteux, Valerie Gras, Yanis Mahboud, Sophie Liabeuf, Youssef Bennis, et al.. Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report. British Journal of Clinical Pharmacology, Wiley, 2019, 85 (4), pp.845-848. ⟨10.1111/bcp.13853⟩. ⟨hal-03564806⟩



Consultations de la notice